Company revenues grew by approximately 32%, reaching about $37 millionGross profit increased by approximately 32%, reaching $26.5 millionNet profit rose by approximately 46%, reaching...
Acquisitions Increase Growth Outlook
(in U.S. dollars unless otherwise noted)
TORONTO, Aug. 9, 2025 /PRNewswire/ - "I am very pleased with our record financial results this...
Reports record profits, with the financial statements reflecting accelerated growth and high profitability, whilst maintaining financial stability
TEL AVIV, Israel , Aug. 11, 2025 /PRNewswire/ -- First...
Strategic acquisition strengthens North America retail presence and operating model, expands Intermex beyond its historically high growth Latin America corridors, and is expected to accelerate digital new customer acquisition
Strategic acquisition strengthens North America retail presence and operating model, expands Intermex beyond its historically high growth Latin America corridors, and is expected to accelerate digital new customer acquisition
LOS ANGELES, Aug. 10, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 405 owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2025.
ANCHORAGE, Alaska, Aug. 08, 2025 (GLOBE NEWSWIRE) -- First National Bank Alaska’s (OTCQX:FBAK) net income for the second quarter of 2025 was $18.4 million, or $5.80 per share. This compares to a net income of $15.6 million, or $4.94 per share, for the same period in 2024.
CALGARY, AB, Aug. 8, 2025 /CNW/ - Crown Capital Partners Inc. ("Crown" or the "Corporation") (TSX: CRWN) today announced its financial results for the...
MONTRÉAL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Dorel Industries Inc. (TSX: DII.B, DII.A) today announced its financial results for the second quarter and six months ended June 30, 2025.
NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Lument Finance Trust, Inc. (NYSE: LFT) ("we", "LFT" or "the Company") today reported its second quarter results. GAAP net...
SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today reported its second quarter 2025 operating and financial results and reviewed recent business highlights.